Skin cancer

Active Research Protocols

  1. 02-C-0211 – Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
  2. 02-C-0313 – Cancer Risk in Xeroderma Pigmentosum Heterozygotes
  3. 11-C-0011 – Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12
  4. 11-C-0048 – A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations
  5. 11-C-0123 – Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction with 12Gy Total Body Irradiation (TBI)
  6. 11-C-0163 – Phase II Study of Lymphocytes Generated with Engineered Cells for Costimulation Enhancement in Patients with Metastatic Melanoma Following Lymphodepletion
  7. 11-C-0170 – A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma
  8. 11-C-0260 – A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
  9. 12-C-0045 – Phase II Study in Patients with Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin
  10. 13-C-0064 – An Open-Label, Multicenter, Single-Arm, Phase I Dose-Escalation with Efficacy Tail Extension Study of RO5185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
  11. 99-C-0099 – Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014